MX390420B - 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos. - Google Patents
3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos.Info
- Publication number
- MX390420B MX390420B MX2019007597A MX2019007597A MX390420B MX 390420 B MX390420 B MX 390420B MX 2019007597 A MX2019007597 A MX 2019007597A MX 2019007597 A MX2019007597 A MX 2019007597A MX 390420 B MX390420 B MX 390420B
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- intensive care
- care treatment
- hydroxybutyrate
- critical illness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438771P | 2016-12-23 | 2016-12-23 | |
| LU100353 | 2017-08-01 | ||
| PCT/EP2017/081394 WO2018114309A1 (en) | 2016-12-23 | 2017-12-04 | 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007597A MX2019007597A (es) | 2019-12-19 |
| MX390420B true MX390420B (es) | 2025-03-20 |
Family
ID=60582587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007597A MX390420B (es) | 2016-12-23 | 2017-12-04 | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190314307A1 (enExample) |
| EP (1) | EP3558291A1 (enExample) |
| JP (1) | JP7174428B2 (enExample) |
| KR (1) | KR20190099469A (enExample) |
| CN (1) | CN110248652B (enExample) |
| AU (1) | AU2017381059B2 (enExample) |
| BR (1) | BR112019012899A2 (enExample) |
| CA (1) | CA3047362A1 (enExample) |
| CO (1) | CO2019007531A2 (enExample) |
| MX (1) | MX390420B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11666548B2 (en) | 2020-06-05 | 2023-06-06 | Baxter International Inc. | Parenteral nutrition formulation |
| US20240269096A1 (en) * | 2022-12-31 | 2024-08-15 | American Ketone Therapeutics LLC | Rapid Onset Therapeutic Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Compounds and Methods for Sepsis Protection and Enhanced Medical Recovery |
| CN117243939B (zh) * | 2023-11-14 | 2025-03-07 | 南京今冉生物新材料科技有限公司 | 一种酮体缓释物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2338090C (en) * | 1998-07-22 | 2009-07-14 | Metabolix, Inc. | Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies |
| CA2339941A1 (en) * | 1998-09-15 | 2000-03-23 | Btg International Limited | Use of cyclic esters of r-3-hydroxybutyrate for treatment of metabolic and neural degenerative disorders |
| DK1648952T3 (en) * | 2003-06-03 | 2018-05-28 | The Us Gov As Represented By The Department Of Health And Human Services | Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives |
| CN100344280C (zh) * | 2005-08-01 | 2007-10-24 | 清华大学 | 3－羟基丁酸及其衍生物的新用途 |
| ES2655367T3 (es) * | 2008-08-21 | 2018-02-19 | Oxford University Innovation Limited | Bebida que comprende éster de hidroxibutirato y uso médico de la misma |
| GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
| GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
-
2017
- 2017-12-04 MX MX2019007597A patent/MX390420B/es unknown
- 2017-12-04 CA CA3047362A patent/CA3047362A1/en active Pending
- 2017-12-04 KR KR1020197021001A patent/KR20190099469A/ko not_active Ceased
- 2017-12-04 EP EP17809280.5A patent/EP3558291A1/en active Pending
- 2017-12-04 AU AU2017381059A patent/AU2017381059B2/en active Active
- 2017-12-04 CN CN201780080218.4A patent/CN110248652B/zh active Active
- 2017-12-04 JP JP2019533344A patent/JP7174428B2/ja active Active
- 2017-12-04 BR BR112019012899A patent/BR112019012899A2/pt not_active Application Discontinuation
- 2017-12-04 US US16/472,600 patent/US20190314307A1/en not_active Abandoned
-
2019
- 2019-07-15 CO CONC2019/0007531A patent/CO2019007531A2/es unknown
-
2023
- 2023-04-18 US US18/135,847 patent/US12409159B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190099469A (ko) | 2019-08-27 |
| BR112019012899A2 (pt) | 2019-12-03 |
| CN110248652B (zh) | 2023-05-26 |
| JP2020502202A (ja) | 2020-01-23 |
| US20230310353A1 (en) | 2023-10-05 |
| CO2019007531A2 (es) | 2020-01-17 |
| US20190314307A1 (en) | 2019-10-17 |
| AU2017381059A1 (en) | 2019-07-25 |
| AU2017381059B2 (en) | 2023-11-30 |
| MX2019007597A (es) | 2019-12-19 |
| NZ755274A (en) | 2025-09-26 |
| CA3047362A1 (en) | 2018-06-28 |
| US12409159B2 (en) | 2025-09-09 |
| JP7174428B2 (ja) | 2022-11-17 |
| EP3558291A1 (en) | 2019-10-30 |
| CN110248652A (zh) | 2019-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200011A1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| UY35821A (es) | Compuesto heterocíclico | |
| CR20160418A (es) | Nuevos compuestos biciclicos de 7 eslabones | |
| CL2018001181A1 (es) | Inhibidores de ret | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
| CO7111287A2 (es) | Composiciones plaguicidas y procesos relacionados | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| BR112018072467A2 (pt) | composições farmacêuticas com permeação aumentada | |
| MX2019010594A (es) | Beta-caseina a2 y prevencion de la inflamacion del intestino. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX2017000222A (es) | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. | |
| BR112017013770A2 (pt) | composições de inibidor de nitrificação microencapsuladas | |
| CY1123465T1 (el) | Αντιβακτηριακες ενωσεις ευρεως φασματος | |
| CY1118883T1 (el) | Μεθοδος παρασκευης βορτιοξετινης | |
| UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| MX2016008719A (es) | Fertilizador de urea con dureza mejorada. | |
| UY37153A (es) | Sulfonilamidas sustituidas para combatir parásitos animales | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| MX2016008491A (es) | Fertilizador con menor contenido de biuret. | |
| EA201700142A1 (ru) | Полимерная композиция для слоя элемента слоя | |
| CO2018004582A2 (es) | Alimentos para aves y, en particular, alimentos para aves de corral, que comprenden derivados sintéticos de capsaicinoides y dichos alimentos para el uso prohiláctico o el tratamiento de la infección por salmonela |